Ryan Dhindsa, M.D., Ph.D.

I am an NRI fellow and instructor at the Duncan Neurological Research Insistute, affiliated with Baylor College of Medicine and Texas Children's Hospital. I am also a consultant for AstraZeneca's Center for Genomic Research. My research focuses on the use of human genetics and functional genomics to understand disease mechanisms and identify targeted therapies. I received my M.D./Ph.D. from Columbia University, where I trained under Dr. David Goldstein at the Institute for Genomic Medicine

I am also the co-founder of
MedChances, a website that provides free medical school admissions predictions. I am originally a native of Reno, Nevada.


Education and work experience
2021 - Present

Baylor College of Medicine

Jan and Dan Duncan Neurological Research Institute & Department of Molecular and Human Genetics


Centre for Genomics Research
Assoc. Principal Scientist

Columbia University

Medical Scientist Training Program.
Laboratory of Dr. David Goldstein, Institute for Genomic Medicine
Thesis: Deciphering gene dysregulation in disease through population and functional genomics

Duke University

Center for Human Genome Variation
bachelor's degree


Google Scholar profile

[31] Effects of protein-coding variants on blood metabolite measurements and clinical biomarkers in the UK Biobank
A Nag, RS Dhindsa, L Middleton, Xiao Jiang, D Vitsios, E Wigmore, EL Allman, A Reznichenko, K Carss, KR Smith, Q Wang, B Challis, DS Paul, AR Harper, S Petrovski. American Journal of Human Genetics. (2023).

[30] Genome-wide prediction of dominant and recessive neurodevelopmental disorder risk genes
RS Dhindsa, B Weido, JS Dhindsa, AJ Shetty, C Sands, S Petrovski, D Vitsios, AW Zoghbi. BioRxiv. (2022)

[29] A minimal role for synonymous variation in human disease
RS Dhindsa, Q Wang, D Vitsios, OS Burren, F Hu, JE DiCarlo, L Kruglyak, DG MacArthur, ME Hurles, S Petrovski. American Journal of Human Genetics. (2022).

[28] DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets
A Raies, E Tulodziecka, J Stainer, L Middleton, RS Dhindsa, P Hill, O Engkvist, AR Harper, S Petrovski, D Vitsios. Communications Biology. (2022)

[27] Influences of rare protein-coding genetic variants on the human plasma proteome in 50,829 UK Biobank participants
RS Dhindsa*, OS Burren*, BB Sun*, BP Prins, D Matelska, E Wheeler, J Mitchell, E Oerton, VA Hristova, KR Smith, K Carss, S Wasilewski, AR Harper, DS Paul, MA Fabre, H Runz, C Viollet, B Challis, A Platt, AstraZeneca Genomics Initiative, D Vitsios, EA Ashley, CD Whelan, MN Pangalos, Q Wang, S Petrovski. BioRxiv. (2022)

[26] Human genetic evidence supports MAP3K15 as an obesity-independent therapeutic target for diabetes
A Nag*, RS Dhindsa*, J Mitchell, C Vasavda, AR Harper, et al. Science Advances. (2022)
*co-first author

[25] Identification of the NRF2 transcriptional network as a therapeutic target for trigeminal neuropathic pain
C Vasavda, R Xu, J Liew, R Kothari, RS Dhindsa, E Semenza, B Paul, et al. Science Advances. (2022).

[24] Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants
B Sun, ... AstraZeneca Genomics Initiative, ..., JD Szustakowski, BW Gibson, MR Miller, CD Whelan. BioRxiv. (2022).

[23] Cancer-driving mutations are enriched in genic regions intolerant to germline variation
D Vitsios*, RS Dhindsa*, J Mitchell, D Matelska, Z Zou, J Armenia, Q Wang, B Sidders, AR Harper, S Petrovski. Science Advances. (2022).
*co-first author

TP53 protein structure

[22] Biliverdin reductase bridges focal adhesion kinase to Src to modulate synaptic signaling
C Vasavda, ER Semenza, J Liew, R Kothari, RS Dhindsa, S Shanmukha, A Lin, R Tokhunts, C Ricco, AM Snowman, LK Albacarys, F Pastore, C Ripoli, C Grassi, E Barone, MD Kornberg, X Dong, BD Paul, SH Snyder. Science Signaling. (2022).

[21] Ancestry adjustment improves genome-wide estimates of regional intolerance
T Hayeck, N Stong, E Baugh, RS Dhindsa, TN Turner, A Malakar, Y Duan, I Ionita-Laza, DB Goldstein, AS Allen. Genetics. (2022).

[20] Association of ultra-rare coding variants with genetic generalized epilepsy: A case–control whole exome sequencing study
M Koko, JE Motelow, KE Stanley, DR Bobbili, RS Dhindsa, P May, Canadian Epilepsy Network, Epi4K Consortium, Epilepsy Phenome/Genome Project, EpiPGX Consortium, EuroEPINOMICS-CoGIE Consortium. Epilepsia. (2022).

[19] High-impact rare genetic variants in severe schizophrenia
AW Zoghbi, RS Dhindsa, TE Goldberg, A Mehralizade, JE Motelow,X Wang, A Alkelai, MB Harms, JA Lieberman, S Markx. PNAS. (2021).

[18] Rare variant contribution to human disease in 281,104 UK Biobank exomes
Q Wang*, RS Dhindsa*, K. Carss*, AR Harper, A Nag, I Tachmazidou, D Vitsios, SVV Deevi, A Mackay, D Muthas, Michael Hühn, S Monkley, H Olsson, S Wasilewski, KR Smith, R March, A Platt, C Haefliger, S Petrovski. Nature. (2021).
*co-first author

Manhattan Plot

[17] Sub-genic intolerance, ClinVar, and the epilepsies: A whole-exome sequencing study of 29,165 individuals
Epi25 Consortium. The American Journal of Human Genetics​, (2021).

[16] Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis
RS Dhindsa, J Mattsson, A Nag, Q Wang, LV Wain, R Allen, EM Wigmore, K Ibanez, D Vitsios, SV Deevi, S Wasilewski, M Karlsson,G Lassi, H Olsson, D Muthas, S Monkley, A Mackay, L Murray, S Young, C Haefliger, FinnGen Consortium, TM Maher, MG Belvisi, G Jenkins, P Molyneaux, A Platt, S Petrovski. Communications Biology. (2021).

Manhattan Plot

[15] Prioritizing non-coding regions based on human genomic constraint and sequence context with deep learning
D Vitsios, RS Dhindsa, L Middleton, AB Gussow, S Petrovski. Nature Communications. (2021).

[14] A Transcriptome‐Based Drug Discovery Paradigm for Neurodevelopmental Disorders
RS Dhindsa, AW Zoghbi, DK Krizay, C Vasavda, DB Goldstein. Annals of Neurology. (2021).

Scientific figure

[13] TMPRSS2 Transcriptional Inhibition as a Therapeutic Strategy for COVID-19
X Wang, RS Dhindsa, G Povysil, A Zoghbi, J Motelow, J Hostyk, N Nickols, M Rettig, DB Goldstein. Preprints. (2020).

[12] Neurodevelopmental deficits and cell-type-specific transcriptomic perturbations in a mouse model of HNRNPU haploinsufficiency
SA Dugger*, RS Dhindsa*, G Sampaio, E Rafikian, S Petri, J Teoh, J Ye, S Colombo, M Yang, M Boland, W Frankel, DB Goldstein. bioRxiv. (2020).
*co-first author


[11] Natural selection shapes codon usage in the human genome
RS Dhindsa, BR Copeland, AM Mustoe, DB Goldstein. American Journal of Human Genetics. (2020).

CDF plot

[10] Ultra-rare genetic variation in the epilepsies: a whole-exome sequencing study of 17,606 individuals
Epi25 consortium. American Journal of Human Genetics. (2019).

[9] G protein-coupled potassium channels implicated in mouse and cellular models of GNB1 Encephalopathy
S Colombo, S Petri, B Shalomov, HP Reddy, G Tabak, RS Dhindsa, S Gelfman, S Teng, D Krizay, EE Rafikian, AK Bera, M Yang, MJ Boland, Y Peng, WN Frankel, N Dascal, DB Goldstein. bioRxiv. (2019).

[8] meaRtools: An R package for the analysis of neuronal networks recorded on microelectrode arrays
S Gelfman, Q Wang, Y Lu, D Hall, CD Bostick, RS Dhindsa, M Halvorsen, KM McSweeney, E Cotterill, T Edinburgh, MA Beaumont, WN Frankel, S Petrovski, AS Allen, MJ Boland, DB Goldstein, SJ Eglen. PLoS computational biology. (2018).

[7] Orion: detecting regions of the human non-coding genome that are intolerant to variation using population genetics
AB Gussow, BR Copeland, RS Dhindsa, Q Wang, S Petrovski, WH Majoros, AS Allen, DB Goldstein. PloS one. (2017).

[6] Molecular Architecture and Neurobiology of the Epilepsies
RS Dhindsa, DH Lowenstein, DB Goldstein. Genomics, Circuits, and Pathways in Clinical Neuropsychiatry. (2016).

[5] Schizophrenia: From genetics to physiology at last
RS Dhindsa, DB Goldstein. Nature. (2016).

Scientific figure

[4] Genetic Discoveries Drive Molecular Analyses and Targeted Therapeutic Options in the Epilepsies
RS Dhindsa, DB Goldstein. Current neurology and neuroscience reports. (2015).

[3] Exome sequencing results in successful riboflavin treatment of a rapidly progressive neurological condition
S Petrovski, V Shashi, S Petrou, K Schoch, KM McSweeney, RS Dhindsa, B Krueger, R Crimian, LE Case, R Khalid, MA El-Dairi, Y Jiang, MA Mikati, DB Goldstein. Molecular Case Studies. (2015).

[2] Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios
X Zhu, S Petrovski, P Xie, EK Ruzzo, Y Lu, KM McSweeney, B Ben-Zeev, A Nissenkorn, Y Anikster, D Oz-Levi, RS Dhindsa, Y Hitomi, K Schoch, RC Spillmann, G Heimer, D Marek-Yagel, M Tzadok, Y Han, G Worley, J Goldstein, Y Jiang, D Lancet, E Pras, V Shashi, D McHale, AC Need, DB Goldstein. Genetics in Medicine. (2015).

[1] Epileptic encephalopathy-causing mutations in DNM1 impair synaptic vesicle endocytosis.
RS Dhindsa, SS Bradrick, X Yao, EL Heinzen, S Petrovski, BJ Krueger, MR Johnson, WN Frankel, S Petrou, RM Boumil, DB Goldstein. Neurology Genetics. (2015).

Scientific figure

[20] Assessing the contribution of rare-to-common protein-coding variants to circulating metabolic biomarker levels via 412,394 UK Biobank exome sequences
A Nag, L Middleton, RS Dhindsa, D Vitsios, E Wigmore, EL Allman, A Reznichenko, K Carss, KR Smith, Q Wang, B Challis, DS Paul, AR Harper, S Petrovski. MedRxiv. (2021).

Get in touch